RHO Phyto’s unique formulations have undergone extensive research and development
to create a line of products that meet the quality and consistency standards that patients
and physicians should expect of medical cannabis products.
The RHO Phyto line consists of advanced oral and topical delivery forms of medical
cannabis extracts including oil drops, sublingual sprays, soft-gel capsules, and topical
creams and gels.
All RHO Phyto formulations are designed to maintain the stability of the cannabinoids to
ensure more consistent clinical effects over the course of treatment. These formulations
are optimized for increased and faster absorption of cannabinoids relative to basic MCT (medium-chain triglyceride) oil formulations.
Avicanna is a Canadian biopharmaceutical company providing advanced cannabinoid solutions through an evidence-based approach. As a multinational organization with vertical integration, Avicanna is focused on utilizing scientific research related to plant-derived cannabinoid products through its internal research platforms, real-world evidence trials, and strategic collaborations with world-class research institutions.
Avicanna’s research and development is conducted at its Canadian headquarters within the Johnson & Johnson Innovation Centre JLABS @ Toronto located in the MaRS Discovery District. Avicanna’s RHO Phyto formulations are scientifically optimized and studied in collaboration with the Christine Allen Research Group (CARG) at the Leslie Dan Faculty of Pharmacy of the University of Toronto, a leading research laboratory for pharmaceutical development in Canada. Avicanna’s partnership with CARG has been focused on formulation optimization, and preclinical characterization of the RHO Phyto products which includes stability, drug release and safety studies.
Avicanna is committed to providing an unparalleled quality of natural cannabinoid solutions
that foster informed communities and improve quality of life.
You must verify that you are 19 years of age or older
to enter this site.